aniracetam

Contents 4 dk okuma

What is Aniracetam?

Aniracetam is the second generation representative of the racetam family of nootropics. While the first synthetic nootropic, piracetam, was developed by UCB Pharma in 1964, aniracetam was developed in the 1970s by structural modification of piracetam in the laboratories of the Swiss pharmaceutical company F. Hoffmann-La Roche (patent 1978).

Piracetam is water soluble while aniracetam fat soluble It is a (lipophilic) compound. This critical difference allows aniracetam to cross the blood-brain barrier much more quickly and efficiently. At the same time, the 4-methoxybenzoyl group added to its structure gives the molecule additional anxiolytic (anxiety-reducing) properties.

in japan Draganon And sarpul It is licensed as a prescription medicine under its trademarks; It also has medicine status in some European countries. In the United States and Türkiye, it is not approved as a medicine and is supplied as a nutritional supplement or research chemical.

Mechanism of Effect

Aniracetam is considered one of the most versatile members of the racetam family, acting simultaneously on multiple neuroreceptor systems. Its basic mechanism is positive allosteric modulation of AMPA receptors; However, in addition to this effect, it also contributes to the metabotropic glutamate, dopamine and nicotinic acetylcholine systems.

target	Impact	Conclusion
AMPA Receptors	Positive allosteric modulation	Fast synaptic transmission, facilitation of learning
mGluR1/5	Antagonism	Anxiety reduction
D2 Receptors	indirect activation	mood improvement
Nicotine Receptors	modulation	focus, attention

Clinical Evidence

Aniracetam is available in Japan under the brand name Draganon. licensed as a prescription drug It is an important indicator that it is based on sufficient safety and efficacy data. Studies conducted by Japanese and Italian research groups constitute the bulk of the aniracetam literature.

Animal studies consistently show that aniracetam enhances memory consolidation and learning. Although human clinical studies remain more limited, significant memory improvements have been reported, particularly in older individuals and populations with mild cognitive impairment. Studies conducted by Sato et al. indicate the potential of aniracetam to slow cognitive decline in Alzheimer's dementia.

There is also human evidence for an anxiolytic effect. In post-seizure anxiety model studies, aniracetam provided significant anxiety reduction with a milder sedation profile compared to standard anxiolytics. This effect, which occurs through the serotonergic and dopaminergic systems, does not cause cognitive suppression, unlike classical benzodiazepines.

Dosage Protocol

Since Aniracetam is fat-soluble, its bioavailability is directly dependent on ingestion with fatty foods. The absorption of aniracetam taken on an empty stomach decreases significantly.

Intended Use	Dose	Timing
Cognitive general	750 mg × 2/day	Morning and afternoon, with meals
hard work	750 mg × 3/day	With every meal
Anxiety support	750 mg × 2/day	Morning and afternoon

Take with oil: Aniracetam MUST be taken with a fatty food – olive oil, avocado, nut butter or a fish oil capsule is sufficient. When taken without fat, bioavailability drops significantly.

Combination suggestions: Cognitive synergistic effects have been reported when used with Piracetam. Adding Alpha-GPC or CDP-Choline prevents choline deficiency headaches that are common with racetam use. The combination with L-Theanine maintains focus while reinforcing the anxiolytic effect.

Safety and Side Effects

Aniracetam is generally a well-tolerated compound and no serious side effects have been observed in available human studies. Long-term clinical use in Japan provides significant real-world data supporting its safety profile.

• Headache: The most common side effect; It is a sign of choline deficiency. It can be resolved by adding CDP-Choline or Alpha-GPC.
• Nausea: It is especially seen when taken on an empty stomach; Always take with food.
• Drowsiness or restlessness: It is rarely reported; It usually resolves with dose reduction.
• Tolerance: It has been reported that tolerance may develop with long-term continuous use. A common practical approach is to take a 1–2 week break after 4–6 weeks of use (cyclic use).

There is no sufficient data for use during pregnancy, breastfeeding and children. Its use is not recommended for these groups. Although it has been theorized that it may affect liver enzyme levels, it has not been clinically documented.

Sources

1. Nakamura K, Tanaka Y. (2001). Antidepressant-like effects of aniracetam in aged rats and its mode of action. Psychopharmacology, 158(2), 205–212. PubMed · PMID 11702095
2. Ito I, et al. (1990). Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. Journal of Physiology, 424, 533–543. PubMed · PMID 1975272
3. Cumin R, et al. (1982). Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology, 78(2), 104–111. PubMed · PMID 6817363
4. Pizzi M, et al. (1999). Aniracetam prevents apoptotic death of cerebral cortex neurons via mGluR1 antagonism. Brain Research, 845(2), 250–256. Search PubMed (match unverified)

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions